This study was a phase IB, single-center, open-label, two part(part A involved dose reduction, and part B involved cohort expansion) clinical trial evaluating the safety and clinical activity of AK104 or AK112 in combination with axitinib in patients with advanced mucosal melanoma.
None
Prior treatment with anti-PD-1/PD-L1/PD-L2 antibody and Axitinib
Is currently participating in a study of an investigational agent or using an investigational device
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment
Has undergone major surgery within 30 days of Study Day 1